Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

[Tongue reconstruction by thoracodorsal perforator flap: A new harvesting technique to reduce morbidity].

Tawa P, Foirest C, Tankéré F, Ouar N, Brault N, Atlan M, Qassemyar Q.

Ann Chir Plast Esthet. 2019 Aug;64(4):368-373. doi: 10.1016/j.anplas.2019.01.001. Epub 2019 Mar 1. French.

PMID:
30827573
2.

Concise syntheses and HCV NS5B polymerase inhibition of (2'R)-3 and (2'S)-2'-ethynyluridine-10 and related nucleosides.

Bennett F, Buevich AV, Huang HC, Girijavallabhan V, Kerekes AD, Huang Y, Malikzay A, Smith E, Ferrari E, Senior M, Osterman R, Wang L, Wang J, Pu H, Truong QT, Tawa P, Bogen SL, Davies IW, Weber AE.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5349-5352. doi: 10.1016/j.bmcl.2017.06.064. Epub 2017 Jun 24.

PMID:
29056248
3.

Identification of novel bifunctional HIV-1 reverse transcriptase inhibitors.

Lai MT, Tawa P, Auger A, Wang D, Su HP, Yan Y, Hazuda DJ, Miller MD, Asante-Appiah E, Melnyk RA.

J Antimicrob Chemother. 2018 Jan 1;73(1):109-117. doi: 10.1093/jac/dkx332.

PMID:
29029095
4.

Can We Make Small Molecules Lean? Optimization of a Highly Lipophilic TarO Inhibitor.

Mandal M, Tan Z, Madsen-Duggan C, Buevich AV, Caldwell JP, Dejesus R, Flattery A, Garlisi CG, Gill C, Ha SN, Ho G, Koseoglu S, Labroli M, Basu K, Lee SH, Liang L, Liu J, Mayhood T, McGuinness D, McLaren DG, Wen X, Parmee E, Rindgen D, Roemer T, Sheth P, Tawa P, Tata J, Yang C, Yang SW, Xiao L, Wang H, Tan C, Tang H, Walsh P, Walsh E, Wu J, Su J.

J Med Chem. 2017 May 11;60(9):3851-3865. doi: 10.1021/acs.jmedchem.7b00113. Epub 2017 Mar 29.

PMID:
28322556
5.

TarO-specific inhibitors of wall teichoic acid biosynthesis restore β-lactam efficacy against methicillin-resistant staphylococci.

Lee SH, Wang H, Labroli M, Koseoglu S, Zuck P, Mayhood T, Gill C, Mann P, Sher X, Ha S, Yang SW, Mandal M, Yang C, Liang L, Tan Z, Tawa P, Hou Y, Kuvelkar R, DeVito K, Wen X, Xiao J, Batchlett M, Balibar CJ, Liu J, Xiao J, Murgolo N, Garlisi CG, Sheth PR, Flattery A, Su J, Tan C, Roemer T.

Sci Transl Med. 2016 Mar 9;8(329):329ra32. doi: 10.1126/scitranslmed.aad7364.

PMID:
26962156
6.

Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.

Côté B, Burch JD, Asante-Appiah E, Bayly C, Bédard L, Blouin M, Campeau LC, Cauchon E, Chan M, Chefson A, Coulombe N, Cromlish W, Debnath S, Deschênes D, Dupont-Gaudet K, Falgueyret JP, Forget R, Gagné S, Gauvreau D, Girardin M, Guiral S, Langlois E, Li CS, Nguyen N, Papp R, Plamondon S, Roy A, Roy S, Seliniotakis R, St-Onge M, Ouellet S, Tawa P, Truchon JF, Vacca J, Wrona M, Yan Y, Ducharme Y.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):917-22. doi: 10.1016/j.bmcl.2013.12.070. Epub 2013 Dec 24.

PMID:
24412110
7.

In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Lai MT, Feng M, Falgueyret JP, Tawa P, Witmer M, DiStefano D, Li Y, Burch J, Sachs N, Lu M, Cauchon E, Campeau LC, Grobler J, Yan Y, Ducharme Y, Côté B, Asante-Appiah E, Hazuda DJ, Miller MD.

Antimicrob Agents Chemother. 2014;58(3):1652-63. doi: 10.1128/AAC.02403-13. Epub 2013 Dec 30.

8.

Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors.

Leclerc JP, Falgueyret JP, Girardin M, Guay J, Guiral S, Huang Z, Li CS, Oballa R, Ramtohul YK, Skorey K, Tawa P, Wang H, Zhang L.

Bioorg Med Chem Lett. 2011 Nov 1;21(21):6505-9. doi: 10.1016/j.bmcl.2011.08.073. Epub 2011 Aug 25.

PMID:
21924609
9.

High-throughput scintillation proximity assay for stearoyl-CoA desaturase-1.

Tawa P, Falgueyret JP, Guiral S, Isabel E, Powell DA, Zuck P, Skorey K.

J Biomol Screen. 2011 Jun;16(5):506-17. doi: 10.1177/1087057111399436. Epub 2011 Mar 15.

PMID:
21406617
10.

Probing cathepsin S activity in whole blood by the activity-based probe BIL-DMK: cellular distribution in human leukocyte populations and evidence of diurnal modulation.

Veilleux A, Black WC, Gauthier JY, Mellon C, Percival MD, Tawa P, Falgueyret JP.

Anal Biochem. 2011 Apr 1;411(1):43-9. doi: 10.1016/j.ab.2010.11.022. Epub 2010 Nov 19.

PMID:
21094118
11.

Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors.

Isabel E, Powell DA, Black WC, Chan CC, Crane S, Gordon R, Guay J, Guiral S, Huang Z, Robichaud J, Skorey K, Tawa P, Xu L, Zhang L, Oballa R.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):479-83. doi: 10.1016/j.bmcl.2010.10.107. Epub 2010 Oct 26.

PMID:
21074991
12.

2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors.

Powell DA, Ramtohul Y, Lebrun ME, Oballa R, Bhat S, Falgueyret JP, Guiral S, Huang Z, Skorey K, Tawa P, Zhang L.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6366-9. doi: 10.1016/j.bmcl.2010.09.094. Epub 2010 Sep 19.

PMID:
20933412
13.

Adenovirus IL-13-induced airway disease in mice: a corticosteroid-resistant model of severe asthma.

Therien AG, Bernier V, Weicker S, Tawa P, Falgueyret JP, Mathieu MC, Honsberger J, Pomerleau V, Robichaud A, Stocco R, Dufresne L, Houshyar H, Lafleur J, Ramachandran C, O'Neill GP, Slipetz D, Tan CM.

Am J Respir Cell Mol Biol. 2008 Jul;39(1):26-35. doi: 10.1165/rcmb.2007-0240OC. Epub 2008 Feb 7.

PMID:
18258919
14.

Effect of cathepsin k inhibitor basicity on in vivo off-target activities.

Desmarais S, Black WC, Oballa R, Lamontagne S, Riendeau D, Tawa P, Duong LT, Pickarski M, Percival MD.

Mol Pharmacol. 2008 Jan;73(1):147-56. Epub 2007 Oct 16.

PMID:
17940194
15.

Solid-phase analogue synthesis of caspase-3 inhibitors via palladium-catalyzed amination of 3-bromopyrazinones.

Isabel E, Aspiotis R, Black WC, Colucci J, Fortin R, Giroux A, Grimm EL, Han Y, Mellon C, Nicholson DW, Rasper DM, Renaud J, Roy S, Tam J, Tawa P, Vaillancourt JP, Xanthoudakis S, Zamboni RJ.

Bioorg Med Chem Lett. 2007 Mar 15;17(6):1671-4. Epub 2007 Jan 11.

PMID:
17251019
16.

Correlating the fractional inhibition of caspase-3 in NT2 cells with apoptotic markers using an active-caspase-3 enzyme-linked immunosorbent assay.

Tawa P, Giroux A, Grimm E, Han Y, Nicholson DW, Xanthoudakis S.

Anal Biochem. 2006 Mar 1;350(1):32-40. Epub 2005 Dec 21.

PMID:
16430849
17.

Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors.

Han Y, Giroux A, Colucci J, Bayly CI, Mckay DJ, Roy S, Xanthoudakis S, Vaillancourt J, Rasper DM, Tam J, Tawa P, Nicholson DW, Zamboni RJ.

Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80.

PMID:
15686936
18.

An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells.

Falgueyret JP, Black WC, Cromlish W, Desmarais S, Lamontagne S, Mellon C, Riendeau D, Rodan S, Tawa P, Wesolowski G, Bass KE, Venkatraman S, Percival MD.

Anal Biochem. 2004 Dec 15;335(2):218-27. Erratum in: Anal Biochem. 2005 May 15;340(2):380.

PMID:
15556560
19.

Solid phase synthesis of selective caspase-3 peptide inhibitors.

Grimm EL, Roy B, Aspiotis R, Bayly CI, Nicholson DW, Rasper DM, Renaud J, Roy S, Tam J, Tawa P, Vaillancourt JP, Xanthoudakis S, Zamboni RJ.

Bioorg Med Chem. 2004 Mar 1;12(5):845-51.

PMID:
14980595
20.

Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors.

Han Y, Giroux A, Grimm EL, Aspiotis R, Francoeur S, Bayly CI, Mckay DJ, Roy S, Xanthoudakis S, Vaillancourt JP, Rasper DM, Tam J, Tawa P, Thornberry NA, Paterson EP, Garcia-Calvo M, Becker JW, Rotonda J, Nicholson DW, Zamboni RJ.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):805-8.

PMID:
14741294
21.

Catalytic activity of caspase-3 is required for its degradation: stabilization of the active complex by synthetic inhibitors.

Tawa P, Hell K, Giroux A, Grimm E, Han Y, Nicholson DW, Xanthoudakis S.

Cell Death Differ. 2004 Apr;11(4):439-47.

22.

Quantitative analysis of fluorescent caspase substrate cleavage in intact cells and identification of novel inhibitors of apoptosis.

Tawa P, Tam J, Cassady R, Nicholson DW, Xanthoudakis S.

Cell Death Differ. 2001 Jan;8(1):30-7.

23.

Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis.

Xanthoudakis S, Roy S, Rasper D, Hennessey T, Aubin Y, Cassady R, Tawa P, Ruel R, Rosen A, Nicholson DW.

EMBO J. 1999 Apr 15;18(8):2049-56.

24.

Cell death attenuation by 'Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex.

Rasper DM, Vaillancourt JP, Hadano S, Houtzager VM, Seiden I, Keen SL, Tawa P, Xanthoudakis S, Nasir J, Martindale D, Koop BF, Peterson EP, Thornberry NA, Huang J, MacPherson DP, Black SC, Hornung F, Lenardo MJ, Hayden MR, Roy S, Nicholson DW.

Cell Death Differ. 1998 Apr;5(4):271-88.

25.

Porins of Haemophilus influenzae type b mutated in loop 3 and in loop 4.

Srikumar R, Dahan D, Arhin FF, Tawa P, Diederichs K, Coulton JW.

J Biol Chem. 1997 May 23;272(21):13614-21.

26.

Ligand-induced conformational change in the ferrichrome-iron receptor of Escherichia coli K-12.

Moeck GS, Tawa P, Xiang H, Ismail AA, Turnbull JL, Coulton JW.

Mol Microbiol. 1996 Nov;22(3):459-71.

PMID:
8939430
27.
28.

pH dependence of CheA autophosphorylation in Escherichia coli.

Conley MP, Berg HC, Tawa P, Stewart RC, Ellefson DD, Wolfe AJ.

J Bacteriol. 1994 Jul;176(13):3870-7.

29.

Kinetics of CheA autophosphorylation and dephosphorylation reactions.

Tawa P, Stewart RC.

Biochemistry. 1994 Jun 28;33(25):7917-24.

PMID:
8011654
30.
31.

Supplemental Content

Support Center